Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:17:48.989Z.
Calculation as of: 2026-10-06T21:17:48.989Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 352cae2fe5eed9f02885becd1bbca6bb54c51239af0254a5780fc03f1b1dafbc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$101.36M
EV/EBIT Ratio
56.60x
TTM Avg
89.36x
3Y Avg
94.92x
5Y Avg
1303.85x
Market Cap
$102.75M
EV/EBIT Ratio
N/A
TTM Avg
28.81x
3Y Avg
28.81x
5Y Avg
28.81x
Market Cap
$103.14M
EV/EBIT Ratio
N/A
TTM Avg
21.29x
3Y Avg
21.29x
5Y Avg
21.29x
Market Cap
$95.14M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.26M
EV/EBIT Ratio
0.64x
TTM Avg
0.59x
3Y Avg
0.59x
5Y Avg
0.59x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OnKure Therapeutics, Inc. (OKUR) | $99.62M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $97.94M | N/A | N/A | N/A | N/A |
| PolyPid Ltd. (PYPD)vs › | $97.90M | 79.82x | 96.06x | 96.06x | 12.74x |
| The Joint Corp. (JYNT)vs › | $101.36M | 56.60x | 89.36x | 94.92x | 1303.85x |
| Korro Bio, Inc. (KRRO)vs › | $97.14M | N/A | N/A | N/A | N/A |
| Anixa Biosciences, Inc. (ANIX)vs › | $102.75M | N/A | 28.81x | 28.81x | 28.81x |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $103.14M | N/A | 21.29x | 21.29x | 21.29x |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $95.14M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $104.26M | 0.64x | 0.59x | 0.59x | 0.59x |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
